FMC Sells India Business: A Small Step in a Long Turnaround

Agricultural chemical company FMC Corp. has agreed to sell its commercial business in India to Crystal Crop Protection Limited for $252 million. The deal, announced on May 7, is expected to close by year-end and will transfer FMC's commercial operations in the country while granting Crystal a license to FMC's brands and preferred access to its R&D pipeline.

This move follows FMC's announcement last July of its intent to sell the India unit, a market that has caused significant headaches. In 2025, the company was forced to take back excess inventory that had built up in its Indian sales channel, leading to a major revenue reversal, a sharp decline in earnings, and a subsequent 92% cut to its dividend.

The primary stated goal of the sale is to reduce FMC's substantial debt load. As of March 31, the company carried over $4.5 billion in debt, meaning this $252 million sale will reduce that total by only about 5.6%.

FMC's stock has plummeted roughly 90% from its early 2022 highs, battered by a combination of patents expiring on key products, a difficult agricultural cycle with low crop prices, and its heavy debt burden. The India sale represents a tangible, albeit small, step in management's attempt to stabilize the company.

For a company drowning in debt, every dollar of cash helps. The $252 million from this sale provides immediate liquidity and slightly improves FMC's leverage ratio. It also allows the company to exit a market that recently caused a major financial disruption, simplifying its global operations.

However, the sale addresses only a fraction of FMC's core challenges. The company's fundamental business is under pressure from multiple sides. Key proprietary chemicals have come off-patent, opening the door to cheaper generic competition and eroding pricing power.

Simultaneously, the broader agricultural market is weak. Low crop prices are squeezing farmers' budgets, making them less likely to spend on premium crop protection chemicals, which hits FMC's sales and profits. This was evident in the last quarter, where both revenue and adjusted EBITDA declined year-over-year.

The company's survival strategy now appears to be a multi-pronged gamble: navigating this tough market, successfully launching new patented molecules from its R&D pipeline, and potentially selling the entire company. CEO Mark Douglas stated in March that there were multiple parties interested in the company's research assets, hinting at a possible buyout. The India sale is a positive step, but the path to a real turnaround remains long and uncertain.